Egyptian expert opinion for the use of sodium‐glucose cotransporter‐2 inhibitors in patients with heart failure with reduced ejection fraction
Explore this paper's citation graph
Summary
An Egyptian consensus document was conducted to demonstrate the importance of and the critical knowledge needed for effective and safe implementation of SGLT2i in the daily practice for the management of patients with a heart failure with reduced ejection fraction.
- Type
- review
- Published
- 2022-02-03
- Cited by
- 3
- References
- 47
- Access
- Open access
- OpenAlex
- https://openalex.org/W4210427521
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:246531108
Keywords
Empagliflozin, Heart failure, Dapagliflozin, Medicine, Ejection fraction
References
- Clinical characteristics and management of hospitalized and ambulatory patients with heart failure–results from ESC heart failure long‐term registry–Egyptian cohort
- Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
- Concomitant diabetes mellitus and heart failure.
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
- IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040.
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY.
- Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
- Diabetes and cardiovascular disease.
- European Society of Cardiology: Cardiovascular Disease Statistics 2017.
- Canagliflozin and cardiovascular and renal events in type 2 diabetes
- Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes
- Gender differences in Egyptian patients hospitalized with heart failure: insights from the European Society of Cardiology Heart Failure Long‐Term Registry
- Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control.
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline
- Practical Guide to Prescribing Sodium-Glucose Cotransporter 2 Inhibitors for Cardiologists.
- Cardiorenal Outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME Trials: A Systematic Review.
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
- Global Updates on Cardiovascular Disease Mortality Trends and Attribution of Traditional Risk Factors
Cited by
- Management of Heart Failure with Reduced Ejection Fraction Globally and in Lebanon: Where Do SGLT-2is Stand?
- Regional expert opinion: Management of heart failure with preserved ejection fraction in the Middle East, North Africa and Turkey
- Telmisartan versus EnalapRil In heart failure with redUced ejection fraction patients with Moderately impaired kidney Functions; randomized controlled trial: “TRIUMF trial”
- Sodium-Glucose Cotransporter-2 Inhibitors: Who, When & How? Guidance for Use from a Multidisciplinary Practical Approach
Related papers
- Review: Dapagliflozin increases, and empagliflozin reduces, adverse renal events in type 2 diabetes
- Comparison of Canagliflozin, Dapagliflozin and Empagliflozin Added to Heart Failure Treatment in Decompensated Heart Failure Patients With Type 2 Diabetes Mellitus
- Quantitative effects of sodium–glucose cotransporter-2 inhibitors dapagliflozin and empagliflozin on quality of life in heart failure patients
- ANMCO statement on the use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure: a practical guide for a streamlined implementation
- Comparison of safety and efficacy of dapagliflozin and empagliflozin in type 2 diabetes mellitus patients in India
- Efficacy of dapagliflozin and empagliflozin for prevention of cardiovascular complications in patients with type 2 diabetes mellitus: a network meta-analysis
- Heart Failure Association of the European Society of Cardiology update on sodium–glucose co‐transporter 2 inhibitors in heart failure
- Sodium-glucose cotransporter type 2 inhibitors: successful running after two hares
- Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review